𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pharmacokinetics and hepatic first-pass effect of (−)-carbovir in the anesthetized rat

✍ Scribed by Inmaculada Soria; Dr. Cheryl L. Zimmerman

Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
300 KB
Volume
16
Category
Article
ISSN
0142-2782

No coin nor oath required. For personal study only.

✦ Synopsis

Studies were designed to allow an in vivo estimation of the hepatic extraction ratio and to test the hypothesis that the pharmacokinetic parameters of (-)-CBV are significantly different during anesthesia. (-)-CBV was administered as an IV bolus followed by IV infusion into either the portal (n = 3) or the jugular (n = 3) veins of anesthetized male Sprague-Dawley rats. These studies indicated that (-)-CBV had a very low hepatic extraction ratio, in agreement with previous (-)-CBV in situ liver perfusion studies. Additionally, anesthesia was shown to alter the pharmacokinetics of (-)-CBV by reducing the total body clearance of this drug.

📜 SIMILAR VOLUMES

Hepatic and intestinal first-pass effect
Hepatic and intestinal first-pass effects of oltipraz in rats
✍ Soo K. Bae; Jin W. Kim; Young H. Kim; Yoon G. Kim; Sang G. Kim; Myung G. Lee 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 1 views

It was reported that the mean value of the extent of absolute oral bioavailability (F) of oltipraz at a dose of 20 mg/kg was 41.2% and only 2.68% of the oral dose was unabsorbed from the gastrointestinal tract in rats. Hence, the low F in rats could be due to considerable first-pass (gastric, intest

Dose-dependent pharmacokinetics and firs
Dose-dependent pharmacokinetics and first-pass effects of mirodenafil, a new erectogenic, in rats
✍ Young H. Choi; Young S. Lee; Soo H. Bae; Tae K. Kim; Bong-Y. Lee; Myung G. Lee 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB 👁 1 views

## Abstract The pharmacokinetics of mirodenafil and its two metabolites, SK3541 and SK3544, after intravenous (5, 10, 20 and 50 mg/kg) and oral (10, 20 and 50 mg/kg) administration of mirodenafil, and the first‐pass effect of mirodenafil after intravenous, oral, intraportal, intragastric and intrad

Pharmacokinetics of a new reversible pro
Pharmacokinetics of a new reversible proton pump inhibitor, YH1885, after intravenous and oral administrations to rats and dogs: hepatic first-pass effect in rats
✍ Kye S. Han; Yoon G. Kim; Joong K. Yoo; Jong W. Lee; Myung G. Lee 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB 👁 1 views

The pharmacokinetics of YH1885 were evaluated after intravenous (iv) and oral administrations of the drug to rats and dogs. The reason for the low extent of bioavailability (F) of YH1885 after oral administration of the drug to rats and the absorption of the drug from various rat gastrointestinal (G

Avoidance of hepatic first-pass effect i
Avoidance of hepatic first-pass effect in the rabbit via rectal route of administration
✍ Nahoko Kurosawa; Eiji Owada; Keiji Ito 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 138 KB 👁 2 views

To assess avoidance of hepatic first-pass effect of drugs, we undertook in situ experiments using rectal administration of lidocaine in the rabbit. We also employed in situ duodenal route to estimate first-pass metabolism across the gastrointestinal mucosa. Rabbits were administered lidocaine HCl in

EXTRAHEPATIC FIRST-PASS METABOLISM OF NI
EXTRAHEPATIC FIRST-PASS METABOLISM OF NIFEDIPINE IN THE RAT
✍ JOHN S. GRUNDY; LISE A. ELIOT; ROBERT T. FOSTER 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 2 views

The peroral (po) bioavailability of nifedipine is reported to range from about 45 to 58% in the rat; this compares favourably to human beings. The metabolism of nifedipine is similar in rats and humans (oxidation of the dihydropyridine ring), with the liver believed to be solely responsible for the